Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Update Il y a 4 ans
Reference: NCT00205478

Woman and Man

Extract

The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.


Inclusion criteria

  • Rheumatoid Arthritis


Links